Avita Medical says RECELL GO maintains FDA breakthrough devices designation

Avita Medical announced that its automated device, RECELL GO, maintains the Food and Drug Administration Breakthrough Device designation for the treatment of acute wounds. RECELL GO represents an evolution of the existing RECELL technology and is designed to automate the process of cell disaggregation. "RECELL GO is a critical component of our platform, and we believe it will greatly accelerate our growth," said Jim Corbett, Chief Executive Officer of AVITA Medical. "Automating the disaggregation process will substantially reduce training requirements, allowing us to leverage selling time more effectively. Additionally, it will ease the burden on physicians and operating room staff, leading to increased adoption. Our dedication to our automation program reflects our continued commitment to innovation and patient care."